Vimarsana
Biggest News Aggregation in the World

Page 30 - Cohort Study News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Cohort Study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Cohort Study Today - Breaking & Trending Today

Vertex and CRISPR Therapeutics Present New Data on More Patients With Longer Follow-Up Treated With - Vimarsana News

Vertex and CRISPR Therapeutics Present New Data on More Patients With Longer Follow-Up Treated With

– Data from 75 patients with transfusion-dependent beta thalassemia or severe sickle cell disease with follow-up of up to 37.2 months continue to demonstrate that exa-cel has the potential to be a one-time functional cure –– Safety profile generally consistent with myeloablative conditioning and autologous stem cell...

Vertex Pharmaceuticals Incorporated: Vertex and CRISPR Therapeutics Announce Acceptance of Late-Breaking Abstract for CTX001 at the 2022 Annual European Hematology Association (EHA) Congress - Vimarsana News

Vertex Pharmaceuticals Incorporated: Vertex and CRISPR Therapeutics Announce Acceptance of Late-Breaking Abstract for CTX001 at the 2022 Annual European Hematology Association (EHA) Congress

- Vertex announces three additional abstracts on the burden of beta thalassemia and sickle cell disease accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR

Vertex and CRISPR Therapeutics Announce Acceptance of Late-Breaking Abstract for CTX001™ at the 2022 - Vimarsana News

Vertex and CRISPR Therapeutics Announce Acceptance of Late-Breaking Abstract for CTX001™ at the 2022

 - Vertex announces three additional abstracts on the burden of beta thalassemia and sickle cell disease accepted for poster presentation –BOSTON & ZUG, Switzerland & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (NASDAQ: CRSP) today announced new late-...

"Pharmacovigilance in hospice/palliative care: Net effect of amitriptyl" by Akram Hussein, Madeline Digges et al. - Vimarsana News

"Pharmacovigilance in hospice/palliative care: Net effect of amitriptyl" by Akram Hussein, Madeline Digges et al.

Background: Real-world effectiveness of interventions in palliative care need to be systematically quantified to inform patient/clinical decisions. Neuropathic pain is prevalent and difficult to palliate. Tricyclic antidepressants have an established role for some neuropathic pain aetiologies, but this is less clear in palliative care. Aim: To describe the real-world use and outcomes from amitriptyline or nortriptyline for neuropathic pain in palliative care. Design: An international, prospective, consecutive cohort post-marketing/phase IV/pharmacovigilance/quality improvement study of palliat...

Source: uow.edu.au
"Appetite-Related Distress Is Burdensome in the Last Sixty Days of Life" by Mariana S. Sousa, Walter Davis et al. - Vimarsana News

"Appetite-Related Distress Is Burdensome in the Last Sixty Days of Life" by Mariana S. Sousa, Walter Davis et al.

Background: People with life-limiting illnesses experience a range of distressing symptoms. Appetite-related symptoms are common, but studies have found varied prevalence and the distress caused has had limited quantification. Objectives: To examine the clinicodemographic factors and trajectory of appetite-related distress in the last 60 days of life. Design/Setting/Subjects: Consecutive cohort of 109,385 patients (359,038 data points) using specialist palliative care services in the Australian Palliative Care Outcomes Collaboration (PCOC). Measurements: Patient-reported appetite-related distr...

Source: uow.edu.au